These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
217 related items for PubMed ID: 30966759
1. Efficacy and Limitations of rCBF-SPECT in the Diagnosis of Alzheimer's Disease With Amyloid-PET. Takahashi M, Tada T, Nakamura T, Koyama K, Momose T. Am J Alzheimers Dis Other Demen; 2019 Aug; 34(5):314-321. PubMed ID: 30966759 [Abstract] [Full Text] [Related]
2. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment. Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC. Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417 [Abstract] [Full Text] [Related]
3. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ, Devous MD, Navitsky M, Lu M, Salloway S, Schaerf FW, Jennings D, Arora AK, McGeehan A, Lim NC, Xiong H, Joshi AD, Siderowf A, Mintun MA, 18F-AV-1451-A05 investigators. Brain; 2017 Mar 01; 140(3):748-763. PubMed ID: 28077397 [Abstract] [Full Text] [Related]
4. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y. Int J Geriatr Psychiatry; 2015 May 01; 30(5):505-13. PubMed ID: 25043833 [Abstract] [Full Text] [Related]
5. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum. Tosun D, Schuff N, Jagust W, Weiner MW, Alzheimer''s Disease Neuroimaging Initiative. Neurodegener Dis; 2016 May 01; 16(1-2):87-94. PubMed ID: 26560336 [Abstract] [Full Text] [Related]
7. Can we predict amyloid deposition by objective cognition and regional cerebral blood flow in patients with subjective cognitive decline? Funaki K, Nakajima S, Noda Y, Wake T, Ito D, Yamagata B, Yoshizaki T, Kameyama M, Nakahara T, Murakami K, Jinzaki M, Mimura M, Tabuchi H. Psychogeriatrics; 2019 Jul 01; 19(4):325-332. PubMed ID: 30688000 [Abstract] [Full Text] [Related]
12. Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study. Boccardi M, Altomare D, Ferrari C, Festari C, Guerra UP, Paghera B, Pizzocaro C, Lussignoli G, Geroldi C, Zanetti O, Cotelli MS, Turla M, Borroni B, Rozzini L, Mirabile D, Defanti C, Gennuso M, Prelle A, Gentile S, Morandi A, Vollaro S, Volta GD, Bianchetti A, Conti MZ, Cappuccio M, Carbone P, Bellandi D, Abruzzi L, Bettoni L, Villani D, Raimondi MC, Lanari A, Ciccone A, Facchi E, Di Fazio I, Rozzini R, Boffelli S, Manzoni L, Salvi GP, Cavaliere S, Belotti G, Avanzi S, Pasqualetti P, Muscio C, Padovani A, Frisoni GB, Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Working Group. JAMA Neurol; 2016 Dec 01; 73(12):1417-1424. PubMed ID: 27802513 [Abstract] [Full Text] [Related]